Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FG 3180

Next Previous
Drug Profile

FG 3180

Alternative Names: 89Zr-DFO-YS5; FG-3180

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fortis Therapeutics
  • Developer Fortis Therapeutics; Kyntra Bio
  • Class Antibodies; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 07 Jan 2026 FibroGen is now called Kyntra Bio
  • 19 Nov 2024 Fibrogen announced the intention to submit an IND application for Prostate cancer in Q1 2025
  • 12 Nov 2024 Fibrogen plans a phase II sub-trial in Prostate cancer (Diagnosis, Metastatic disease, Hormone refractory) in USA (IV) in Q1 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top